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Abbreviations 33 
 34 
aTAAD  acute type A aortic dissection 35 
CT   computed tomography 36 
cTAAD  subacute or chronic type A aortic dissection 37 
D   diameter 38 
EKG   electrocardiogram 39 
EuroSCORE II European System for Cardiac Operative Risk Evaluation II 40 
F   female 41 
IRAD   International Registry of Acute Aortic Dissections 42 
L   length 43 
LCCA   left common carotid artery 44 
M   male 45 
N   number 46 
NA   not applicable 47 
NBS   non-bare stent 48 
PA   pseudoaneurysm 49 
RCA   right carotid artery 50 
RFV   right femoral vein 51 
SD   standard deviation 52 
SG   stent-graft 53 
TA   transapical 54 
TAVR   transcatheter aortic valve replacement 55 
TAx   transaxillary 56 
TEVAR  thoracic endovascular aortic repair 57 
TF   transfemoral 58 
 59 
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ABSTRACT 61 
 62 
OBJECTIVE: Thoracic endovascular aortic repair (TEVAR) has demonstrated 63 
encouraging results and is gaining increasing acceptance as a treatment option for 64 
aortic aneurysms and dissections. Yet, its role in managing proximal aortic 65 
pathologies is unknown - this is important because in proximal (Stanford type A) 66 
aortic dissections, 10-30% are not accepted for surgery, and 30-50% are technically 67 
amenable for TEVAR. We describe our case series of type A aortic dissections treated 68 
using TEVAR. 69 
 70 
METHODS: Between year 2009 and 2016, 12 patients with acute, subacute or 71 
chronic type A aortic dissection with the proximal entry tear located between the 72 
coronaries and brachiocephalic artery were treated with TEVAR at 3 centers. Various 73 
stent-graft configurations were used to seal the proximal entry tear in the ascending 74 
aorta under rapid pacing.  75 
 76 
RESULTS: 12 patients (9 male, 3 female), mean age 81±7 years, EuroSCORE II 77 
9.1±4.5, underwent TEVAR for the treatment of type A aortic dissection. Procedural 78 
success was achieved in 11/12 patients (91.7%). There was one intra-procedural death 79 
and one minor stroke. No additional deaths at 30 days. At 36 months, there were 4 80 
further deaths (all from non-aortic causes). The mean survival of these 4 deceased 81 
was 23 months (range 15-36 months). Follow-up computed tomography demonstrated 82 
favorable aortic remodeling. 83 
 84 
CONCLUSION: TEVAR is feasible and reveals promising early results in selected 85 
patients with type A aortic dissection who are poor candidates for surgical repair. The 86 
current iteration of stent-graft technology however needs to be adapted to the specific 87 
features of the ascending aorta. 88 
 89 
Abstract word count: 248  90 
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Central Message 91 
TEVAR in type A aortic dissection is feasible in selected patients. Favorable 92 
aortic remodelling occurs in type A (and B) dissections. Thus TEVAR may be an 93 
option in patients at high risk for surgery.  94 
 95 
Perspective Statement 96 
TEVAR offers a potential treatment option in a subset of patients with type A 97 
aortic dissection at high surgical risk but with suitable anatomy. With TEVAR, 30 98 
day survival is >90% in these high surgical risk patients. With this proof of 99 
concept study, broader application may be possible with further specific 100 
technological advances. 101 
 102 
Central Picture legend 103 
Successful interventional treatment of a type A aortic dissection using TEVAR 104 
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INTRODUCTION 106 
 107 
The surgical mortality and morbidity remains high for proximal (Stanford 108 
type A) aortic dissections, particularly in the elderly with significant co-109 
morbidities, despite recent strides to improve its surgical technique and 110 
management (1, 2). Considering the Western demographics with increasing 111 
aging population and variety of co-morbidities which portend inherent increased 112 
surgical risks, the concept of endovascular stent-grafting also known as thoracic 113 
endovascular aortic repair (TEVAR) (a catheter-based non-surgical technique) in 114 
patients with thoracic aortic disease is increasingly attractive, propelled by the 115 
desire to minimize surgical risks. TEVAR has been shown to initiate healing and 116 
remodelling of the dissected aorta, by excluding and depressurizing the false 117 
lumen (3-5). To date, TEVAR strategies appear encouraging in the treatment of 118 
various aortic pathologies (6-10). The technology has been embraced without 119 
level I evidence for the treatment of distal (Stanford type B) aortic dissections, 120 
and even used to treat acute proximal (Stanford type A) aortic dissections (11). 121 
However, the complexity of the anatomy in the ascending aorta continues to be a 122 
major obstacle for the use of endovascular technologies. 123 
Acute type A aortic dissection usually requires very urgent surgical repair 124 
of the ascending aorta (12-14); selected cases however may qualify for TEVAR as 125 
an option in scenarios of unacceptably high surgical risk. According to the 126 
International Registry of Acute Aortic Dissections (IRAD), 86% patients qualify 127 
for surgical replacement of the ascending aorta, 23% or 12% require additional 128 
partial or total arch replacement, respectively (15). Overall, on aggregate 91% of 129 
patients in this registry underwent surgical repair under cardiopulmonary 130 
bypass with 25% in-hospital mortality (15, 16). A less traumatic repair of type A 131 
aortic dissection using TEVAR, where applicable, may potentially lower the 132 
procedural/in-hospital mortality risk, particularly as the technology improves.  133 
Surgical repair leaves a patent false lumen in both the aortic arch and 134 
descending aorta in 75% patients, those who survive often require distal re-135 
interventions (15, 16). One solution may be a two-stage hybrid procedure, 136 
whereby initially, surgery is performed to replace the ascending aorta together 137 
with aorto-brachiocephalic artery bypass without hypothermic circulatory 138 
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arrest. This is followed on a second occasion by surgery for left carotid artery 139 
bypass and TEVAR to retrogradely place an endovascular stent-graft in the 140 
thoracic aorta transfemorally in the same setting. The stent-graft excludes the 141 
retrogradely perfused distal false lumen (17). The objective of such an approach 142 
is to avoid surgery on the arch, and to complete the repair with an aortic stent-143 
graft in a minimally invasive way. Such approach not only minimizes the 144 
procedural risks, but also enables careful evaluation of the distal false lumen 145 
prior to stent-graft placement. Alternatively, one-stage hybrid procedures 146 
combining open (surgical) insertion of an tube-graft in the ascending aorta with 147 
head vessel transposition and antegradely placing  an endovascular  stent-graft 148 
in the arch and descending aorta are feasible (18), but require the skills of both a 149 
cardiac and endovascular specialist and lack the precision of the two-stage 150 
hybrid procedure (19). Moreover, there is some resistance to apply such one-151 
stage hybrid procedures in acute type A aortic dissections, because experts are 152 
aware that the fragile outer aortic wall and friable dissecting lamella are prone to 153 
injury or perforation by antegrade positioning of the stent-graft under 154 
conditions of circulatory arrest. At present there are no dedicated stent-grafts for 155 
the ascending aorta, in particular for the repair of aortic dissections; such 156 
challenges will certainly be addressed by customized stent-graft technology in 157 
the near future. Nevertheless, the concept of a one-stage hybrid repair with 158 
antegrade stent-graft placement may become part of a therapeutic 159 
armamentarium for complex type A dissections with distal malperfusion; while a 160 
multi-stage hybrid repair incorporating retrograde stent-graft placement may 161 
become a preferred option in stable situations.  162 
From an anatomical perspective, 30–50% patients with type A aortic 163 
dissection are amenable to TEVAR (20, 21). Thus in the future more patients may 164 
be considered suitable for TEVAR with life-long follow-up. The ultimate goal is a 165 
fully catheter-based approach to repair the ascending aorta that minimizes 166 
procedural risk and initiates healing (as documented in type B dissections where 167 
interventional entry closure is associated with thrombosis of the false lumen and 168 
favorable aortic remodelling) (3, 4, 6, 7). Such approach is feasible with current 169 
technology (22-25). Here, we describe our 12-case series of type A aortic dissections 170 
treated using TEVAR. 171 
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 172 
METHODS 173 
 174 
Patient selection 175 
Between year 2009 and 2016, 12 patients with type A aortic dissection 176 
consisting of an isolated dissection entry in the ascending aorta, referred to the 177 
University Heart Centre (Rostock, Germany), CHU (Liege, Belgium) and Royal 178 
Brompton Hospital (London, UK) were selected and subjected to TEVAR. These 179 
patients were selected for TEVAR because of high co-morbidities and anatomic 180 
suitability, e.g. aortic dimensions suitable to accommodate a ready-made 181 
commercial stent-graft. All had elevated anesthetic risk score (American Society 182 
of Anesthesiologists classification IV or greater), New York Heart Association 183 
class III or IV, chronic lung disease and/or renal impairment. Decisions regarding 184 
treatment required consensus between cardiac surgeons and cardiologists, with 185 
the patients giving informed written consent. TEVAR in this setting was 186 
approved by the internal review board of each center. All patients had EKG-gated 187 
computed tomography (CT) (Figure 1) and echocardiography for the diagnosis 188 
and assessment of aortic dissection. Echocardiography allowed assessment of 189 
the aortic valve, left ventricular function, presence/absence of tamponade, and 190 
interrogation of the supra-aortic vessels.   191 
 192 
TEVAR procedure 193 
     Procedural planning was based on contrast-enhanced EKG-gated CT 194 
(Figure 1), which was evaluated using standard software (TeraRecon, or 195 
3Mensio) to select the appropriate stent-graft size; the diameter of the stent-196 
graft was chosen according to an estimate of the previous (before dissection) 197 
aortic dimension to avoid oversizing. The stent-grafts used were usually ZENITH 198 
TX2 (Cook, Bloomington, Indiana), GORE C-Tag (Gore Ltd. London, UK) or Relay 199 
NBS (Bolton, Barcelona, Spain). They are made of a self-expanding nitinol stent 200 
platform covered with polyester fabric. They are packed and mounted onto a 201 
catheter-based delivery system. Figure 2 and Videos 1-3 show a typical TEVAR 202 
procedure. With the patient under general anesthesia, a temporary pacing wire 203 
was placed in the right ventricle and vascular access for the TEVAR device (22-204 
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24F) obtained via right femoral arterial cut-down. The true lumen of the aorto-205 
ilio-femoral arterial route was navigated using a soft long hydrophilic guide wire 206 
(Terumo, Inc.) protruding ahead of a pigtail catheter to reach the left ventricle 207 
under fluoroscopy and ultrasound guidance (transesophageal 208 
echocardiography) (26). Once the pigtail is in the left ventricle, the soft 209 
hydrophilic guide wire was exchanged to a stiff 270cm length guide wire through 210 
the pigtail catheter. The stiff guide wire has a soft spiral tip that sits within the 211 
left ventricular cavity. The stent-graft was then delivered along the stiff guide 212 
wire to its intended position, where its distal landing zone is between ‘distal to 213 
the coronary ostia’ and ‘proximal to the brachiocephalic artery’ in the ascending 214 
aorta. In this position, the distal tip of the delivery system may cross the aortic 215 
valve. For stent-graft deployment, rapid right ventricular pacing at 180 bpm was 216 
used to reduce the systolic blood pressure to ≤50mmHg in order to avoid 217 
displacement (windsock effect) of the stent-graft during its deployment, thus 218 
enabling its precise placement. At the end of the procedure, the temporary 219 
pacing wire was removed, the femoral artery access site closed, and the patient 220 
extubated and transferred to the coronary care unit. Procedural success was 221 
defined as successful placement of the stent-graft in its intended position with 222 
sealing of the entry tear. 223 
 224 
Follow-up 225 
Overall aortic and true lumen diameters were assessed at the level of 226 
sinotubular junction, ostium of the brachiocephalic artery and left subclavian 227 
artery. Follow-up CT scans were performed approximately at 6 months and then 228 
annually post TEVAR. 229 
 230 
Statistical analysis 231 
Descriptive statistic was used to characterize patients, procedural data 232 
and individual survival. 233 
 234 
RESULTS  235 
 236 
A total of 12 patients with proximal (type A) aortic dissection were 237 
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selected for TEVAR (Table 1). There were 10 DeBakey type II and 2 DeBakey 238 
type I dissections. The mean age ± standard deviation (SD) was 81 ± 7 years; 239 
male:female ratio was 9:3. All patients were of advanced age with chronic lung 240 
disease, coronary artery disease and/or renal impairment. The mean EuroSCORE 241 
II was 9.1 ± 4.5 (SD). The median time from onset of symptoms/diagnosis to 242 
TEVAR was 24 days. There were 6 cases of acute (≤14 days after symptom onset) 243 
and 6 cases of subacute (15 days to 3 months) or chronic (>3 months) aortic 244 
dissections. The false lumen of the dissection expanded significantly causing 245 
various complications, including dyspnoea, hoarseness or laryngeal nerve 246 
dysfunction. There was a history of chest and back pain in all cases. There were 247 
no significant aortic insufficiency, no clinically apparent distal malperfusion 248 
syndromes and no distal interventions required. 249 
Procedural success was 91.7% (11/12) (Table 1). There was one death 250 
due to cardiac tamponade from wire induced perforation of the left ventricle. All 251 
remaining 11 patients were discharged alive within 2 weeks of TEVAR. The 252 
mean procedural time was 86 ± 33 (SD) minutes. Stent-grafts were deployed 253 
under rapid right ventricular pacing which achieved a mean systolic pressure of 254 
34 ± 15 (SD) mmHg. The mean follow-up time was 21.1 ± 11.8 (SD) months 255 
(range 0 - 36 months) post TEVAR. There were 4 deaths, one each at 15, 19, 23 256 
and 36 months (Table 1). All appeared to have died from natural causes. The 257 
mean survival in those who died during follow-up was 23 months. 258 
Follow-up CT scans revealed thrombosis or remodelling of the stent-graft 259 
excluded false lumen. The diameter of the aorta at the sinotubular junction was 260 
not enlarged and remained similar to the normal aorta post TEVAR (Figure 3).  261 
 262 
DISCUSSION 263 
 264 
There is general consensus that proximal aortic dissection or any major 265 
pathology involving the ascending aorta should be subjected to surgical repair. 266 
However, 10-30% of patients with acute type A aortic dissection are considered 267 
too high risk for surgical repair and would therefore receive only medical 268 
therapy with associated high mortality of ≈60% in the intermediate term (13, 15, 269 
27, 28). Surgical mortality is 10-25% (16, 27) depending on the complexity of the 270 
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operation and the clinical status of the patient. In our hands, the procedural 271 
mortality of TEVAR was 8%, which compares favorably with the published early 272 
endovascular mortality of 11% [18, 19]. Interestingly, the most anticipated 273 
complications such as major stroke did not occur. One minor stroke (transient) 274 
and one death from guidewire perforation of the left ventricle leading to fatal 275 
tamponade occurred. 276 
We estimate the number of TEVAR procedures performed in this study 277 
relative to all emergency surgeries for type A aortic dissection in our 3 centers to 278 
be ≈2%, or 6-17% of inoperable type A cases (assuming the incidence of type A 279 
dissection ≈40 cases/year for a typical aortic center; therefore across 3 centers 280 
spanning the study period of 6 years, the total number of cases = 40 cases x 6 281 
years x 3 centers = 720 cases; generally 10-30% of type A dissections are 282 
inoperable (15)).  283 
Successful sealing of the false lumen entry with no development of 284 
proximal type I endoleak were achieved. During follow-up, no cases of endoleak 285 
were identified which is encouraging and different to ≈10% incidence reported 286 
elsewhere (29). In selecting the appropriate size of stent-grafts, we chose the 287 
diameter of the stent-grafts according to an estimate of the previous (before 288 
dissection) aortic dimension to avoid oversizing. The goal was to re-shape the 289 
dissected ascending aorta, cover the entry tear and depressurize the false lumen 290 
(30, 31); there is a fine balance between fixation to the aortic wall and the degree 291 
of intimal injury caused by the self-expanding stent-graft. However, once 292 
precisely deployed, the process of remodelling of the false lumen appears similar 293 
between the proximal and distal dissection, and takes place usually within one 294 
year, similar to that reported elsewhere (32, 33). Most of our cases were 295 
DeBakey type II dissections, and even in the 2 cases of type I dissection (patients 296 
2 and 3 in Table 1), favorable aortic remodelling of the descending aorta were 297 
observed. It seems that the therapeutic concept of closing the entry and 298 
depressurizing the false lumen in type B (distal) aortic dissection holds true also 299 
in type A (ascending) aortic dissection (3, 4). As long as the false lumen is 300 
thrombosed and depressurized, survival even with type A aortic dissection can 301 
be improved by TEVAR (34). In addition, the patients’ exposure to unacceptable 302 
risk of surgery is minimized. 303 
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Current literature (mostly single or small case series) underlines the 304 
feasibility of proximal endovascular procedures over more than 10 years, 305 
performed by surgeons and interventionalists (Table 2). Our series over 6 years 306 
with a mean follow-up of >20 months (range up to 3 years) underlines the fact 307 
that in the setting of significant co-morbidities representing high surgical risk 308 
but with suitable anatomy, TEVAR can be a viable alternative to surgical repair. 309 
In other words, it is feasible to avoid high risk/ complex surgery, and apply a less 310 
traumatic intervention to obtain a similar or better short-term outcome in a 311 
subset of elderly patients with significant co-morbidities. The advantages of 312 
TEVAR includes the avoidance of thoracotomy, cardiopulmonary bypass, 313 
selective head perfusion and associated surgical risks in an elderly population, 314 
often in a critical condition (35). If the high initial ≈60% mortality of type A 315 
aortic dissection can be successfully lowered by TEVAR, such less traumatic 316 
strategy may potentially become an option in a broader spectrum of patients 317 
(27). As TEVAR is a fairly expensive procedure, its associated lower 318 
risks/complications and shorter lengths of hospital stay compared to surgery 319 
may potentially demonstrate its advantages in terms of cost and clinical outcome 320 
over surgery. 321 
TEVAR will not be feasible in every patient; the most suitable anatomy is 322 
where the entry tear of the dissection is located in the middle portion of the 323 
ascending aorta. Entry tears close to the coronaries or aortic valve lack a suitable 324 
length of landing zone. Entry tears close to the brachiocephalic artery would 325 
require complex branching/fenestration strategies. Currently, only a limited 326 
number of choices are available regarding the type of stent-graft and delivery 327 
system because relatively large diameter and short length stent-grafts are 328 
required. Existing delivery systems need to be modified for ascending aorta 329 
intervention: a long nosecone can either damage the aortic valve or increase the 330 
chance of left ventricular perforation by the stiff guidewire, as occurred in one of 331 
our patients.  332 
On a technical note, with the use of rapid ventricular pacing no 333 
misplacement of these short stent-grafts was seen. Pacing is probably the most 334 
efficient method to avoid windsock effect of the left ventricle, enabling precise 335 
stent-graft placement. Transoesophageal echocardiography is also useful in 336 
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guiding stent- graft positioning and assessing sealing of the entry tear (26). 337 
It should be emphasized that a multidisciplinary team, consisting of 338 
cardiac and vascular surgeons and cardiologists, should select suitable patients 339 
for the procedure, similar to transcatheter aortic valve replacement (TAVR). 340 
Looking forward, we believe TEVAR in the ascending aorta is a definitive 341 
solution for patients not accepted for surgery, or a bridging solution in case of 342 
unclear neurological diagnosis (e.g., major stroke) to buy time for reconstructive 343 
surgery. Selection process in patients not suitable for surgical valve replacement 344 
may even be conceivable for combined TAVR- TEVAR technology, in an attempt 345 
to treat variants of aortic dissection including those with compromised aortic 346 
valve function. It should also be emphasised that in the acute setting there is a 347 
need to identify and transfer type A aortic dissection patients to a specialized 348 
unit as quickly as possible; once the dissection has produced coronary 349 
obstruction (usually the right coronary artery) with ensuing (right) ventricular 350 
infarction and heart failure, it is a difficult situation to retrieve by either 351 
endografting or conventional surgery. 352 
 353 
Study limitations 354 
While we could demonstrate proof of concept and feasibility of TEVAR in 355 
the ascending aorta with encouraging results, we did not examine possible 356 
detrimental effects such as stiffening of the ascending aorta by the stent, lowered 357 
vascular compliance, negative effects on the aortic valve function or 358 
hypertension in this observational study. Our sample size is relatively small, but it 359 
represents one of the biggest case-series in the field and supports the feasibility of 360 
TEVAR in practical terms. We have no control group (medically treated or surgery) 361 
for comparison, but historical data suggests that surgery confers 25% peri-operative 362 
mortality, and medical treatment is associated with 60% mortality (13, 15, 27, 28). A 363 
propensity-matched comparison prior to any randomized study would probably 364 
be the next step to strengthen the data on TEVAR in the proximal aorta; current 365 
technology is unlikely to allow a broader application yet. 366 
 367 
Conclusion 368 
TEVAR is feasible and reveals promising early results in selected patients 369 
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with proximal (type A) aortic dissection who are poor candidates for surgical repair. 370 
The current iteration of stent-graft technology however needs to be adapted to the 371 
specific features of the ascending aorta before TEVAR as a concept emerges for 372 
broader applications in the proximal aorta.  373 
  374 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
14 
 
Figure legends 375 
 376 
Figure 1. From top to bottom: 2-dimensional transverse and coronal section of a 377 
localized proximal aortic dissection (type A) with a large entry between the 378 
aortic valve and brachiocephalic artery; 3-dimensional reconstruction prior to 379 
treatment. 380 
 381 
Figure 2. TEVAR procedural sequence for placing a covered stent-graft to treat a 382 
type A aortic dissection. (A) Aortogram and set-up showing a right ventricular 383 
pacing wire and transesophageal echo probe; (B) Stent-graft deployment during 384 
rapid pacing; (C) Completed deployment of the stent-graft; (D) Aortogram 385 
demonstrating procedural success. 386 
 387 
Figure 3. From top to bottom: 2-dimensional transverse and coronal sections of a 388 
proximal (type A) aortic dissection before (left) and after stent-grafting (right), 389 
demonstrating TEVAR reconstruction and remodelling of the aorta. The bottom 390 
panels demonstrate the successful intervention in 3-dimensional reconstruction. 391 
 392 
Video 1. Before TEVAR. Digital subtraction angiogram showing a large tear in the 393 
ascending aorta, and a marker pigtail, pacing wire and transoesophageal 394 
echocardiography probe in place. 395 
 396 
Video 2. During TEVAR. Fluoroscopic display of the launch of a self-expanding 397 
Viabahn stent-graft in the brachiocephalic artery followed by a self-expanding C-398 
Tag stent-graft covering the ascending aorta under rapid pacing. 399 
 400 
Video 3. After TEVAR. Completion angiogram after placement of the Viabahn 401 
stent-graft in the brachiocephalic artery and C-Tag stent-graft in the ascending 402 
aorta; the entry to the dissection is sealed and flow is preserved to the 403 
brachiocephalic and coronary arteries.  404 
  405 
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Table 1 
Patient Age & Sex Diagnosis 
Euroscore 
II SG SG size DxL (mm) 
Procedure 
duration 
(min) 
Procedural 
complications  
Follow-up 
(months) 
 
1 74 M cTAAD (DeBakey II) 6.9 Cook 34x77 90 None 32 
2 75 M aTAAD (DeBakey I) 8.1 
Bolton 
34x60 140 None 29 
NBS 
3 87 M aTAAD (DeBakey I) 13.4 
Bolton  
34x60 79 None 35 
 NBS 
4 89 M cTAAD (DeBakey II) 15.0 Cook 36x77 149 None 15, † 
5 90 M cTAAD (DeBakey II) 19.3 Cook 36x77 70 
Ventricular 
rupture, 
tamponade 
0, † 
6 69 M aTAAD (DeBakey II) 3.9 Cook 34x77 61 None 36, † 
7 75 M cTAAD (DeBakey II) 4.9 
Bolton 
34x60 70 None 
24 
NBS  
8 87 M cTAAD (DeBakey II) 9.4 Cook 36x77 49 
Minor  
15 Stroke 
9 87 F 
 aTAAD 
(DeBakey II, 
post TAVR) 
7 Optimed 32x50 120 None 23, † 
10 83 M cTAAD (DeBakey II) 6.9 Cook 34x77 89 None 19, † 
11 75 F aTAAD (DeBakey II) 5.9 Cook 34x77 60 none 5 
12 75 F aTAAD (DeBakey II) 8.9 
Gore + 
Viabahn in 
innominate 
artery 
34x100 60 none 0 
 
Abbreviations:  aTAAD (acute type A aortic dissection), cTAAD (subacute or chronic type A aortic dissection), D 
(diameter), F (female), L (length), M (male), NBS (non-bare stent), SG (stent-graft), TAVR (transcatheter aortic valve 
replacement). † indicates deceased. 
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Abbreviations: LCCA (left common carotid artery), N (number), PA (pseudoaneurysm), RCA (right 
carotid artery), RFV (right femoral vein), TA (transapical), TAx (transaxillary), TF (transfemoral).  
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